Full history for every metric is available with a Kvantra account
Key financial summary
Financials in CHF| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | CHF m | 128 | 160 | 183 | 212 | 225 | 269 | 307 | 336 |
| Operating profit | CHF m | 1.93 | 4.95 | ||||||
| Net profit | CHF m | -0.9 | 6.8 | -5.8 | 0.6 | 3.5 | 8.3 | 14.9 | 18.8 |
| EPS reported | CHF | 0.67 | 1.20 | ||||||
| Operating cashflow per share | CHF | 2.80 | 2.37 | ||||||
| Capex per share | CHF | 2.05 | 2.27 | ||||||
| FCF per share | CHF | 0.75 | 0.10 | ||||||
| Free cash flow | CHF m | 9.34 | 1.21 | ||||||
| Net debt | CHF m | 97 | 181 | ||||||
| Book value equity | CHF m | 276 | 282 | ||||||
| Book value per share | CHF | 22.17 | 22.60 | ||||||
| Number of shares | m | 12.45 | 12.47 | ||||||
| DPS (TTM paid) | CHF | 0.00 | 0.00 |
Financial summary
Financials in CHF| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 131.64 | - | ||||||
| P/B LTM | x | 3.97 | 3.67 | ||||||
| P/S LTM | x | 4.07 | 3.37 | ||||||
| P/FCF LTM | x | 117.19 | 859.37 | ||||||
| EV/EBITDA LTM | x | 26.68 | 35.94 | ||||||
| EV/Sales LTM | x | 4.53 | 3.96 | ||||||
| Earnings Yield LTM | % | 0.76% | 1.44% | ||||||
| FCF Yield | % | 0.85% | 0.12% | ||||||
| Quality | |||||||||
| ROE | % | 3.03% | 5.35% | ||||||
| ROIC | % | 0.28% | 0.61% | ||||||
| Operating margin | % | 0.72% | 1.61% | ||||||
| Gross margin | % | 75.89% | 77.48% | ||||||
| FCF/Sales | % | 3.47% | 0.39% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +139.29% | - | ||||||
| Sales Growth YoY | % | +19.76% | +29.92% | ||||||
| Net Income Growth YoY | % | +136.65% | - | ||||||
| FCF Growth | % | -55.52% | -93.81% | ||||||
| Operating Profit Growth | % | -75.41% | -42.59% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | 0.00% | 0.00% | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.06 | 0.01 | ||||||
| Net Debt/EBITDA | x | 2.73 | 5.36 | ||||||
| EBIT/Net interest | x | 0.26 | 0.47 | ||||||
| Net debt/market cap | % | 8.88% | 17.52% | ||||||
| Net debt/Equity | x | 0.35 | 0.64 | ||||||
| Gross debt/equity | x | 0.57 | 0.74 | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Medartis Holding AG is a global medical technology firm that develops, manufactures, and distributes implantable solutions. These advanced medical devices are utilized worldwide for the surgical stabilization of bone fractures in both the upper and lower extremities, in addition to addressing complex cranio-maxillofacial surgical needs. The company's portfolio features osteosynthesis instruments, marketed under the APTUS and MODUS brands, specifically designed for various body regions including the hand, wrist, elbow, shoulder, foot, and ankle, as well as for facial and skull procedures involving the mandible, midface, orthognathic structures, and cranium. Medartis serves a diverse clientele comprising surgeons, hospitals, medical centers, and group purchasing organizations. The company, founded in 1997, is headquartered in Basel, Switzerland.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Based on consensus from external analysts. Not Kvantra's opinion.
Medartis Holding AG is a global medical technology firm that develops, manufactures, and distributes implantable solutions. These advanced medical devices are utilized worldwide for the surgical stabilization of bone fractures in both the upper and lower extremities, in addition to addressing complex cranio-maxillofacial surgical needs. The company's portfolio features osteosynthesis instruments, marketed under the APTUS and MODUS brands, specifically designed for various body regions including the hand, wrist, elbow, shoulder, foot, and ankle, as well as for facial and skull procedures involving the mandible, midface, orthognathic structures, and cranium. Medartis serves a diverse clientele comprising surgeons, hospitals, medical centers, and group purchasing organizations. The company, founded in 1997, is headquartered in Basel, Switzerland.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free